• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

SERUM DIAGNOSIS OF MALIGNANT POTENTIAL OF ESOPHAGEAL CANCER

Research Project

Project/Area Number 12671200
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Digestive surgery
Research InstitutionCHIBA UNIVERSITY

Principal Investigator

SHIMADA Hideaki  Chiba University, Graduate School of Medicine, Lecturer, 大学院・医学研究院, 講師 (20292691)

Co-Investigator(Kenkyū-buntansha) OCHIAI Takenori  Chiba University, Graduate School of Medicine, Professor, 大学院・医学研究院, 教授 (80114255)
HAYASHI Hideki  Chiba University, Graduate School of Medicine, Assistant, 大学院・医学研究院, 助手 (20312960)
NABEYA Yoshihiro  Chiba University, University Hospital, Assistant, 医学部付属病院, 助手 (40322028)
舟波 裕  千葉大学, 医学部附属病院, 助手 (70312949)
松原 久裕  千葉大学, 医学部附属病院, 助手 (20282486)
Project Period (FY) 2000 – 2002
Project Status Completed (Fiscal Year 2002)
Budget Amount *help
¥3,300,000 (Direct Cost: ¥3,300,000)
Fiscal Year 2002: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 2001: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 2000: ¥1,500,000 (Direct Cost: ¥1,500,000)
KeywordsEsophageal Cancer / Serum Marker / Serum p53 antibody / VEGF / PDECGF / Midkine / ICTP / SCC-Ag / 腫瘍マーカー / p53抗体 / VEGF / PyNPase / FasL / IAP / 血液パネル検査 / 悪性度診断
Research Abstract

In esophageal cancer patients, genetic analysis of cancer cells has been reported as an important tool to evaluate malignant potential of cancer cells. However, since protein analyzes reqiure tumor specimen and complicated techniques, a simpler and less invasive method for evaluating gene expression level is necessary for clinical application. Recently, gene & protein expression level in patients with various cancer has been made possible by measuring serum concentration with enzyme-linked immunosorbent assay (ELISA) have been reported to be raised in various cancer patients and was the prognostic factor closely associated with advanced tumor stage. We, therefore, analyzed serum markers in 340 patients with primary and recurrent esophageal cancer prior to treatment to determine the clinicopathological significance of serum markers. We found that most of the patients had high serum levels and, moreover, that high serum level was associated with advanced tumor stage treatment response and patietns' survival.

Report

(4 results)
  • 2002 Annual Research Report   Final Research Report Summary
  • 2001 Annual Research Report
  • 2000 Annual Research Report
  • Research Products

    (26 results)

All Other

All Publications (26 results)

  • [Publications] Shimada H: "Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma"Surgery. 132(1). 41-47 (2002)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Shimada H: "Prognostic significance of serum thymidine phosphorylase concentration in esophageal squamous cell carcinoma"Cancer. 94(7). 1947-1954 (2002)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Nabeya Y: "Serum cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as a prognostic tumor marker in patients with esophageal squamous cell"Cancer. 94(4). 940-949 (2002)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, Funami Y, Hayashi H, Gunji Y, Suzuki T, Kobayashi S, Ochiai T: "Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma"Cancer. 89(8). 1677-1683 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Shimada H, Okazumi S, Takeda A, Nabeya Y, Matsubara H, Funami Y, Hayashi H, Gunji Y, Suzuki T, Ochiai T: "Presence of serum p53 antibodies is associated with decreased in vitro chemosensitivity in patients with esophageal cancer"Surg Today. 31(7). 591-596 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Shimada H, Takeda A, Nabeya Y, Okazumi SI, Matsubara H, Funami Y, Hayashi H, Gunji Y, Kobayashi S, Suzuki T, Ochiai T: "Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma"Cancer. 92(3). 663-669 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Nabeya Y, Shimada H, Okazumi S, Matsubara H, Gunji Y, Suzuki T, Ochiai T: "Serum cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as a prognostic tumor marker in patients with esophageal squamous cell carcinoma"Cancer. 94(4). 940-949 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Shimada H, Takeda A, Shiratori T Nabeya Y, Okazumi S, Matsubara H, Funami Y Hayashi H, Gunji Y, Kobayashi S, Suzuki T, Ochiai T: "Prognostic significance of serum thymidine phosphorylase concentration in esophageal squamous cell carcinoma"Cancer. 94(7). 1947-1954 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Shimada H, Nabeya Y, Okazumi S Matsubara H, Funami Y, Shiraton T, Hayashi H, Takeda A, Ochiai T: "Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma"Surgery. 132(1). 41-47 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Shimada H, Ochiai T, Nomura F: "Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors : a multiinstitutional analysis by the Japan p53 Antibody Research Group"Cancer. 97(3). 682-689 (2003)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Shimada H, Kitabayashi H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, Miyazawa Y, Shiratori T, Uno T, Itoh H, Ochiai T: "Treatment response and prognosis of patients after recurrence of esophageal cancer"Surgery. 133(1). 24-31 (2003)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Shimada H, Nabeya Y, Okazumi S, Matsubara H, Kadomatsu K, Muramatsu T, Ikematsu S, Sakuma S, Ochiai T: "Increased serum midkine concentration as a possible tumor marker in patients with superficial esophageal cancer"Oncol Rep.. 10(2). 411-414 (2003)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Shimada H: "Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma"Surgery. 132(1). 41-47 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Shimada H: "Prognostic significance of serum thymidine phosphorylase concentration in esophageal squamous cell carcinoma"Cancer. 94(7). 1947-1954 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Nabeya Y: "Serum cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as a prognostic tumor marker in patients with esophageal squamous cell"Cancer. 94(4). 940-949 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Takeda A et al.: "Monitoring of p53 autoamtibodies after resection of colorectal cancer : Relationship to operative curability"Eur.J.Surg. 167(1). 50-53 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Shimada H, et al.: "Presence of Serum p53 Antibodies is Associated with Decreased In Vitro Chemosensitivity in Patients with Esophageal Cancer"Surgery Today. 31. 591-596 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Shimada H et al.: "Clinical Signifcance of Serum Vascular Endothelial Growth Factor in Esophageal Cancer Patients"Cancer. 92. 663-669 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Nabeya Y et al.: "Serum Cross-linked Carboxyterminal Telopeptide of Type I Collagen (ICTP) as a Useful Prognostic Tumor Marker in Patients with Esophageal Squamous Cell Carcinoma"

    • Related Report
      2001 Annual Research Report
  • [Publications] Akihiko Takeda, et al.: "Serum p53 antibody as a useful marker for monitaring of treatment of superficical colorectal adenocarcinoma after endoscopic resection"Int J. Clin Oncol. 6. 45-49 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Hideaki Shimada, et al.: "Serum p53 antibody is a useful tumor marker in the patients with superficial esophageal cancer"Cancer. 89. 1677-1683 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Akihiko Takeda: "Serum p53 antibody as a useful marker for monitaring of treatment of superficical colorectal adenocarcinoma after endoscopic resection."Int J Clin Oncol. 6. 45-49 (2001)

    • Related Report
      2000 Annual Research Report
  • [Publications] Akihiko Takeda: "Serum p53 antibodies monitoring after colorectal surgery."Eur.J.Surg. 167(1). 50-53 (2001)

    • Related Report
      2000 Annual Research Report
  • [Publications] Akihiko Takeda: "Impact of circulating p53 autoantibody monitoring after endoscopic resection in mucosal gastric cancer."Endoscopy. 32. 740-741 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] Akihiko Takeda: "Clinical significance of serum vascular endothelial growth factor in colorectal cancer patients : correlation with clinicopathological factors and tumor markers."Oncol Report. 7. 333-338 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] Hideaki Shimada: "Serum p53 antibody is a useful tumor marker in the patients with superficial esophageal cancer"Cancer. 89. 1677-1683 (2000)

    • Related Report
      2000 Annual Research Report

URL: 

Published: 2000-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi